Physician profile
David Suhocki
NPI 1861483414
$6,226.48
in general payments reported to CMS, 2019-2025
11 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $284 · 2023: $469 · 2024: $4,497 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $1,529 · Education: $99.99 · Travel and Lodging: $43.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $1,529.00 |
| Education | $99.99 |
| Travel and Lodging | $43.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,206.30 | 2021-2025 | |
| Janssen Biotech, INC. | $359.88 | 2025 | Tremfya |
| Amgen INC. | $213.05 | 2022-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $146.26 | 2023-2025 | Sotyktu |
| Ucb, INC. | $113.53 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $48.32 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $42.78 | 2024-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $40.47 | 2024 | |
| Genzyme Corporation | $27.37 | 2025 | |
| Pfizer INC. | $23.39 | 2023 | |
| Organon LLC | $5.13 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Suhocki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.